On January $1,2023,$ PulaskI, Incorporated, acquired a $60$ percent Interest in the common stock of Sheridan, Incorporated, for $$334,200.$ Sheridan's book value on that date consisted of common stock of $$100,000$ and retained earnings of $$197,600.$ Also, the acquisition$-$date falr value of the $40$ percent noncontrolling interest was $$222,800.$ The subsidlary held patents $($with a $10-$year remaining life$)$ that were undervalued within the company's accounting records by $$75,700$ and also had unpatented technology $(15$year estimated remaining life$)$ undervalued by $$51,300.$ Any remaining excess acquisition$-$date fair value was assigned to an indefiniteIlved trade name. Since acquisition, Pulaski has applied the equity method to its Investment in Sheridan account. At year$-$end, there are no intra$-$entity payables or recelvables.

Intra$-$entity inventory sales between the two companies have been made as follows:

$\backslash$table$[[$Year cost to Pulaski,Transfer Price,Ending Balance $($at$,],[$to Sheridan,transfer price$),,],[2023,$$$124,800,$$$156,000,$$$52,000$

That's all. No more information. If you cannot solve it$.$ Change another one.